Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 3, 2007, Pages 440-444

  Leung, Nelson ^a,b   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Kumar, Shaji K ^a   Hayman, Suzanne R ^a   Fervenza, Fernando C ^a   Cha, Stephen S ^a   Gertz, Morie A ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; SERUM ALBUMIN; TROPONIN T;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOTRANSPLANTATION; BLOOD; FEMALE; FOLLOW UP; HEART MUSCLE; HOSPITALIZATION; HUMAN; KIDNEY; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PREDICTION AND FORECASTING; PROTEINURIA; STEM CELL TRANSPLANTATION; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY; MALE; MIDDLE AGED; MYOCARDIUM; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROTEINURIA; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TROPONIN T;

EID: 34748854224     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02450706     Document Type: Article

References (19)

1. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 349: 583-596, 2003
2. Gertz MA, Kyle RA: Amyloidosis: Prognosis and treatment. Semin Arthritis Rheum 24: 124-138, 1994
3. Kyle RA, Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 32: 45-59, 1995
4. Kyle RA, Greipp PR, O'Fallon WM: Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases. Blood 68: 220-224, 1986
5. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA: Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 16: 104-109, 1999
6. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336: 1202-1207, 1997
7. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, Jones LA, Cohen AS: Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100: 290-298, 1996
8. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 140: 85-93, 2004
9. Dember LM, Sanchorawala V, Seldin DC, Wright DG, La-Valley M, Berk JL, Falk RH, Skinner M: Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 134: 746-753, 2001
10. Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA: Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis 46: 270-277, 2005
11. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N, Harousseau JL: Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 101: 766-769, 1998
12. Mollee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C, Stewart AK: Autologous stem cell transplantation in primary systemic amyloidosis: The impact of selection criteria on outcome. Bone Marrow Transplant 33: 271-277, 2004
13. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Gertz MA: Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19: 3350-3356, 2001
14. Wilson DM, Bergert JH, Larson TS, Liedtke RR: GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 30: 646-652, 1997
15. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122: 78-84, 2003
16. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157-163, 2004
17. Okano K, Yumura W, Nitta K, Honda K, Uchida K, Nihei H: Evaluation of prognostic factors for myeloperoxidase anti-neutrophil cytoplasmic antibody- (MPO-ANCA) associated glomerulonephritis. Clin Nephrol 55: 275-281, 2001
18. D'Amico G: Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: Survey of the recent literature. Am J Kidney Dis 20: 315-323, 1992
19. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS: Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104: 1881-1887, 2004